Dihydropyrimidine Dehydrogenase Testing prior to Treatment with 5-Fluorouracil, Capecitabine, and Tegafur: A Consensus Paper.

doi:10.1159/000510258

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Dihydropyrimidine Dehydrogenase Testing prior to Treatment with 5-Fluorouracil, Capecitabine, and Tegafur: A Consensus Paper.

Oncology research and treatment - 1 Jan 2020

Wörmann Bernhard, Bokemeyer Carsten, Burmeister Thomas, Köhne Claus-Henning, Schwab Matthias, Arnold Dirk, Blohmer Jens-Uwe, Borner Markus, Brucker Sara, Cascorbi Ingolf, Decker Thomas, de Wit Maike, Dietz Andreas, Einsele Hermann, Eisterer Wolfgang, Folprecht Gunnar, Hilbe Wolfgang, Hoffmann Jürgen, Knauf Wolfgang, Kunzmann Volker, Largiadèr Carlo R, Lorenzen Sylvie, Lüftner Diana, Moehler Markus, Nöthen Markus M, Pox Christian, Reinacher-Schick Anke, Scharl Anton, Schlegelberger Brigitte, Seufferlein Thomas, Sinn Marianne, Stroth Matthias, Tamm Ingo, Trümper Lorenz, Wilhelm Martin, Wöll Ewald, Hofheinz Ralf-Dieter

Abstract excerpt

BACKGROUND: 5-Fluorouracil (FU) is one of the most commonly used cytostatic drugs in the systemic treatment of cancer. Treatment with FU may cause severe or life-threatening side effects and the treatment-related mortality rate is 0.2-1.0%. SUMMARY: Among other risk factors associated with increased toxicity, a genetic deficiency in dihydropyrimidine dehydrogenase (DPD), an enzyme responsible for the metabolism...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Antimetabolites, Antineoplastic

Share to Austria

Share to Capecitabine

Share to Consensus

Share to Dihydrouracil Dehydrogenase (NADP)

Share to Fluorouracil

Share to Practice Guidelines as Topic

Share to Switzerland

Source

Open in PubMed

Identifiers

PMID: 33099551
DOI: 10.1159/000510258

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Dihydropyrimidine Dehydrogenase Testing prior to Treatment with 5-Fluorouracil, Capecitabine, and Tegafur: A Consensus Paper.PMID 33099551Read ↗

[Dihydropyrimidine déhydrogenase (DPD) deficiency screening and securing of fluoropyrimidine-based chemotherapies: Update and recommendations of the French GPCO-Unicancer and RNPGx networks].Semantic proximity Read ↗

DPYD genotyping and dihydropyrimidine dehydrogenase (DPD) phenotyping in clinical oncology. A clinically focused minireview.Semantic proximity Read ↗

Improving safety of fluoropyrimidine chemotherapy by individualizing treatment based on dihydropyrimidine dehydrogenase activity - Ready for clinical practice?Semantic proximity Read ↗

Dihydropyrimidine Dehydrogenase Deficiency and Implementation of Upfront DPYD Genotyping.Semantic proximity Read ↗

Fluoropyrimidine chemotherapy: recommendations for DPYD genotyping and therapeutic drug monitoring of the Swiss Group of Pharmacogenomics and Personalised Therapy.Semantic proximity Read ↗

Consensus of experts from the Spanish Pharmacogenetics and Pharmacogenomics Society and the Spanish Society of Medical Oncology for the genotyping of DPYD in cancer patients who are candidates for treatment with fluoropyrimidines.Semantic proximity Read ↗

Should DPD analysis be required prior to prescribing fluoropyrimidines?Semantic proximity Read ↗

Clinical Pharmacogenetics Implementation Consortium guidelines for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing.Semantic proximity Read ↗

All You Need to Know About DPYD Genetic Testing for Patients Treated With Fluorouracil and Capecitabine: A Practitioner-Friendly GuideSemantic proximity Read ↗

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing: 2017 Update.Semantic proximity Read ↗

[Phenotype- or genotype test for dihydropyrimidin dehydrogenase deficiency before treatment with a fluoropyrimidine].Semantic proximity Read ↗

DPYD genotyping and predicting fluoropyrimidine toxicity: where do we stand?Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.